Antibacterial and Antibiofilm Activities of Psychorubrin, a Pyranonaphthoquinone Isolated From *Mitracarpus frigidus* (Rubiaceae)

Ari S. O. Lemos¹, Lara M. Campos¹, Lívia Melo¹, Maria C. M. R. Guedes¹, Luiz G. Oliveira², Thiago P. Silva³, Rossana C. N. Melo³, Vinicius N. Rocha⁴, Jair A. K. Aguiar², Ana C. M. Apolônio⁵, Elita Scio¹ and Rodrigo L. Fabri¹*

¹ Bioactive Natural Products Laboratory, Department of Biochemistry, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil, ² Laboratory of Glycoconjugate Analysis, Department of Biochemistry, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil, ³ Laboratory of Cellular Biology, Department of Biology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil, ⁴ Department of Veterinary Medicine, Faculty of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil, ⁵ Laboratory of Bacterial Physiology and Molecular Genetics, Department of Parasitology, Microbiology and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil

Psychorubrin, a natural pyranonaphthoquinone found in different plants, has become an interesting compound in the search for new antimicrobial therapeutic agents. Here, we investigated the potential antagonistic activity of psychorubrin against planktonic and biofilm bacteria. First, psychorubrin was tested against several Gram-positive and Gram-negative bacteria strains by a broth microdilution susceptibility method. Second, bacterial killing assay, bacterial abundance, and membrane viability were evaluated. The nucleotide leakage assay was used to verify membrane destabilization while antibiofilm activities were analyzed by the effect on established biofilm, static biofilm formation, isolation of biofilm matrix assay and scanning electron microscopy. In parallel, the combinatorial effect of psychorubrin and chloramphenicol was evaluated by the checkerboard method. Psychorubrin was active against Gram-positive bacteria, showing rapid time-dependent kinetics of bacterial killing, amplified nucleotide leakage, and greater activity against the methicillin-resistant species (MRSA) *Staphylococcus aureus* 33591 and 33592 and *Staphylococcus pyogenes* 10096. Psychorubrin also interfered with the composition of the biofilm matrix by reducing the total content of carbohydrates and proteins. A synergic effect between psychorubrin and chloramphenicol was observed for *S. aureus* 33592 and *S. pyogenes* 10096 while an additive effect was detected for *S. aureus* 33591. Our findings demonstrate, for the first time, an antagonistic activity of psychorubrin against bacteria not only in their planktonic forms but also in biofilms, and identify bacterial membranes as primary targets for this compound. Based on these observations, psychorubrin has a good potential for the design of novel antimicrobial agents.

Keywords: psychorubrin, antibacterial activity, MRSA, *Mitracarpus frigidus*, biofilm control
INTRODUCTION

Staphylococcus aureus is a major human pathogen that can cause varied diseases, ranging from minor skin infections to severe systemic diseases such as sepsisemia and pneumonia (reviewed in Kobayashi et al., 2015). Moreover, new resistant strains of S. aureus have arisen with tentative treatments of the pathologies caused by this bacterium (Choo, 2017; Oestergaard et al., 2017). The bacteremia caused by methicillin-resistant S. aureus (MRSA), for example, is associated with increased morbidity and mortality in adults and its frequency has become greater in hospital institutions (Wilson et al., 2017). In 2004, the Center for Disease Control showed that MRSA proportion was higher than 50% in intensive care unit patients, considering the hospitals that integrated the National Nosocomial Infections Surveillance System [NNIS] (2004). However, multidrug-resistant organisms have not emerged only in the hospital environment. In recent years, due to the exacerbated use of antibiotics, MRSA has also been increasingly found in community-onset infections (Choo, 2017). MRSA is widely prevalent worldwide, with rates highest than 50% reported in North and South America, Asia, and Malta (Stefani et al., 2012). Diverse antimicrobial classes including the β-lactams, the glycopeptides, and the fluoroquinolones have been recognized as a major problem in public health because of their resistance (Mai et al., 2017).

Streptococcus pyogenes (group A streptococcus) is another common human pathogen. Although most infections caused by S. pyogenes are benign and have short duration, this agent may cause late sequelae such as post-streptococcal acute glomerulonephritis, rheumatic fever, streptococcal toxic shock syndrome, necrotizing fasciitis, and other localized or systemic infections, which may present a fulminate evolution (reviewed in Carapetis et al., 2005; Imohl et al., 2017). The global impact of invasive S. pyogenes disease is high with, at least, 663,000 new cases and 163,000 deaths worldwide each year (Carapetis et al., 2005).

Although resistant bacteria in their free-living forms have been a major concern for the health system, when they congregate in large numbers to form a biofilm, the problem is even bigger (Ribeiro et al., 2016). In fact, biofilms, densely packed communities of microbial cells growing in a living or inert surface and surrounded by a self-produced polymeric matrix, requires much higher doses of antibiotics (10–1000 times) for bacterial killing and can lead to chronic and persistent infections (Mishra and Wang, 2017). This occurs because biofilm protects bacteria against several physicochemical aggressions, including ultraviolet light, heavy metals, acidity, modulation in hydration or salinity, and phagocytosis (Lebeaux et al., 2014). Thus, bacteria growing in a biofilm are highly resistant to antibiotic treatment and host immune defense and, once established, a biofilm becomes difficult to eradicate (Wu et al., 2015).

Because antimicrobial resistance and biofilm formation are a global public health challenge, there is a striking need of development of new biologically active molecules against multidrug-resistant bacteria and the adoption of medicinal crude extracts of plants to treat infectious diseases (Subramani et al., 2017). In this context, our group has been studying different potential bioactive antibacterial compounds (Pinto et al., 2017a,b), including a natural product termed psychorubrin, a naphthoquinone commonly found in a variety of plants (Fabri et al., 2009, 2012).

Psychorubrin (Figure 1) has been associated with diverse biological activities, such as antitumoral (Hayashi et al., 1987; Fabri et al., 2012), cytotoxic (Hayashi et al., 1987), leishmanicidal (Fabri et al., 2012), and antiplasmodial (Endale et al., 2012) actions. In a previous work, we isolated psychorubrin from Mitracarpus frigidus (Fabri et al., 2009), a native species of Brazil (Pereira et al., 2006) and identified a promising potential antimicrobial property for this compound (Fabri et al., 2012). Here, the planktonic antibacterial activities of psychorubrin were investigated in detail as well as the potential bacterial biofilm control by this agent. By using different approaches, we found a consistent antagonistic activity for psychorubrin, which affects both bacterial forms and biofilms of Gram-positive bacteria, especially the multidrug-resistant S. aureus 33591 and 33592 in addition to S. pyogenes 10096. We also identified that the antimicrobial action of psychorubrin is linked with disruption of the bacterial cell membrane structure.

MATERIALS AND METHODS

Plant Material

The aerial parts of Mitracarpus frigidus (Willd. Ex Roem. & Schult.) K. Shum (Rubiaceae) were collected in Juiz de Fora, Minas Gerais State, Brazil, in May 2011. The plant was identified by Dr. Tatiana Konom from the Ecological and Socio environmental Core of Macaé/UFRJ. A voucher specimen (CESJ 46076) was deposited at the Leopoldo Krieger Herbarium at the Federal University of Juiz de Fora (Brazil).

Extraction and Reisolation

A crude dichloromethane (CH2Cl2) extract was prepared from Mitracarpus frigidus as before (Fabri et al., 2009). The isolation and structural elucidation of psychorubrin were performed as previously described in Fabri et al. (2012).
Microbial Strains
The psychorubrin extract was screened by serial dilution assay against the following Gram-positive microorganisms: Staphylococcus aureus ATCC 25923, Staphylococcus aureus ATCC 33591 (Gentamicin and methicillin-resistant Staphylococcus aureus – MRSA), Staphylococcus aureus ATCC 33592 (Methicillin-resistant Staphylococcus aureus – MRSA) and Streptococcus pyogenes ATCC 10096 as well as the Gram-negative microorganisms Escherichia coli ATCC 10536, Klebsiella pneumoniae ATCC 4532 and Pseudomonas aeruginosa ATCC 9027. For subsequent tests, only S. aureus ATCC 33591, S. aureus ATCC 33592 and S. pyogenes ATCC 10096 were selected. The strains were cultured overnight at 37°C in Mueller Hinton agar (MHA) before each experiment.

Serial Dilution Assay for Determination of the Minimal Inhibitory Concentration (MIC)
The minimal inhibitory concentration (MIC) of psychorubrin was determined by microdilution techniques in Mueller Hinton broth (MHB) as described (CLSI, 2014). Bacteria were cultured at 37°C for 24 h in MHA. The psychorubrin stock solution was twofold diluted ranging from 320 to 2.5 µg mL⁻¹ (final volume = 80 µL) with final dimethyl sulfoxide (DMSO) concentration ≤ 1%. Then, 100 µL of MHB and 20 µL of 10⁸ CFU mL⁻¹ (according to McFarland turbidity standards) bacterial suspensions were inoculated onto microplates, and the test was performed in a 200 µL final volume. Plates were incubated at 37°C for 24 h. Experiments were performed simultaneously for bacterial growth control (MHB + bacteria + psychorubrin vehicle) and sterility control (MHB + psychorubrin vehicle) as well as for the positive controls with chloramphenicol (100–0.2 µg mL⁻¹) and ciprofloxacin (500–0.24 µg mL⁻¹). MIC values were calculated from the highest dilution showing a complete inhibition of the tested strain. Analyses were done in triplicate. Compounds were considered significantly active when the MIC values were ≤ 10 µg mL⁻¹ (Kuete, 2017).

Studies of Planktonic Bacteria
Bacterial Growth Curve
Psychorubrin was tested to determine the time-kill kinetics of strains. Saline suspensions of freshly grown bacterial strains (10⁸ CFU mL⁻¹) were inoculated with different concentrations of psychorubrin (MIC, 0.5MIC, and 0.25MIC values) supplemented with MHB. Optical density (OD) at 600 nm was recorded in a spectrophotometer (Multiskan Go, Thermo Scientific, Waltham, MA, United States) at 2, 4, 6, 8, and 24 h of bacterial growth at 37°C as before (Pinto et al., 2017a,b). Graphs of turbidity versus incubation time were plotted. As a positive control, chloramphenicol was added. For bacterial growth control, groups consisting of MHB medium containing psychorubrin vehicle plus strains were used. Experiments were performed in triplicate (Babii et al., 2016).

Bacterial Abundance
Slides prepared in a cytocentrifuge were used to quantify bacteria as before (Silva et al., 2014). Bacterial strains maintained in saline were inoculated into MHB containing psychorubrin (MIC value) and incubated at 37°C during 24 h. As a positive and negative control for this assay, chloramphenicol and psychorubrin vehicle at MIC values were added, respectively, to the groups containing bacterial strains. After diluting 10 times (1 mL) in saline, samples were fixed with sterile free-particle 37% formaldehyde to a final concentration of 2%, stained with 4′,6-Diamidino-2-Phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, United States) for DNA recognition (final concentration of 0.01 µg mL⁻¹) and placed in mega funnels (Shandon Mega Funnel, Thermo, United Kingdom) for immediate centrifugation in a cytocentrifuge (Shandon Cytospin 4, Thermo, United Kingdom), at 452 g at high acceleration during 10 min. Acceleration and speed were determined as the Cytospin manufacturer manual. Cells were analyzed under a fluorescence microscope (BX-60, Olympus, Melville, NY, United States) with a U-MWU2 filter (330–385 nm excitation wavelengths). For bacteria quantification, 20 random fields were counted for each sample at 1,000x magnification using an ocular grid. By applying a dilution factor (10x), the total bacterial count was obtained.

Nucleotide Leakage
Nucleotide release was evaluated as before (Tang et al., 2008) with some modifications. Overnight bacterial cultures at 37°C were washed and resuspended in 10 mM PBS (pH 7.4), reaching a final
density of nearly 10^8 cells mL^{-1}. Strains were then incubated with psychorubrin at MIC value during different times (2, 4, 6, and 8 h) while strains incubated with 10 mM PBS (pH 7.4) served as control groups. After incubation, cell suspensions were centrifuged at 10,000 g for 10 min; the supernatants were diluted appropriately, and the OD at 260 nm was recorded in a spectrophotometer (Multiskan Go, Thermo Scientific, Waltham, MA, United States) at room temperature (25°C). Experiments were performed in triplicate.

**Checkerboard Test**

The potential synergistic activity of psychorubrin and chloramphenicol was investigated by the checkerboard test (Pillai et al., 2005), which enables calculation of the fractional inhibitory concentration (FIC) index (FICI), that is the sum of the FICs (ΣFIC) of both agents. FICI values were interpreted as follows: FICI ≤ 0.5 synergy; 0.5 < FICI ≤ 1 additivity; 1 < FICI ≤ 2 indifference or no effect; and FICI ≥ 2 antagonism (Božič et al., 2014). The MIC of the two assayed agents was used for the FICI tested dilutions.

Assays were done using 96-well polystyrene microtiter plates with MHB, psychorubrin and chloramphenicol in twofold serial concentrations. Bacterial suspensions were prepared at a final concentration of 10^8 CFU mL^{-1}, incubated overnight at 37°C and read in a spectrophotometer (Multiskan Go, Thermo Scientific, Waltham, MA, United States). Tests were done in triplicate.

**Biofilm Studies**

**Effect on Established Biofilms**

The effect of psychorubrin on established biofilms was tested as before (Nostro et al., 2007) with some alterations. Briefly, biofilms of S. aureus 33591, S. aureus 33592 and S. pyogenes 10096 strains were generated with each of these organisms using 96-well polystyrene microtiter plates filled with MHB, 1% glucose and cells (conc 10 cells/mL) during 24 h at 37°C. Then, the planktonic cells were gently removed and, after washing with saline (three times), the wells were filled with 200 µL of psychorubrin (twofold dilutions), with MIC in the range of four-fold dilution. Incubation was performed at 37°C during 24 h. OD was evaluated at 492 nm at time 0 and at 24 h after incubation. As a positive control for this assay, chloramphenicol was added. For biofilm studies, biofilms were transferred to screw cap bottles containing 2 mL of distilled water. The bottles were sonicated for 5 min in an ultrasonic water bath and vortexed vigorously for 1 min to disrupt the biofilms. Cell suspensions were then pooled, centrifuged and the supernatants collected for subsequent evaluation of the total content of proteins and carbohydrates.

**Scanning Electron Microscopy (SEM)**

*Staphylococcus aureus* 33591, S. aureus 33592, and S. pyogenes 10096 strains were seeded in MH agar, incubated for 24 h at 37°C, and inoculated into a tube containing 5 mL of BHI broth with 1% glucose. Then, 500 µL of the inoculated broth (10^8 UFC mL^{-1}) was added in plated of 24 wells containing round glass coverslips (13 mm, Glasscyto®). The treatment (n = 3 wells) was done by adding 500 µL of the psychorubrin (final concentration per well = MIC). For negative (n = 3) and positive (n = 3) controls 500 µL of sterile water or chloramphenicol (MIC) were added, respectively. Biofilms on glass coverslips (13 mm, Glasscyto®) were cultured for 24 h at 37°C and fixed in 2.5% glutaraldehyde for 30 min at room temperature (Riedel-de-Haen, Germany) in 0.1 M cacodylate buffer (pH 7.2). Coverslip-adherent cells were post-fixed with osmium tetroxide, and dehydrated through a graded series of ethanol solutions (30, 50, 70, 90% and twice 100%) for 15 min at each concentration. Cells were then critical point dried in carbon dioxide. Coverslips were mounted on aluminum holders, sputtered with 5 nm gold, and analyzed in a scanning electron microscope (JEOL JSM-6390LV, Tokyo, Japan) for observation of the biofilms and bacterial morphology.

**Statistical Analysis**

Results are expressed as mean values with the standard error. The statistical analyses were performed using ANOVA test followed by Bonferroni to compare the controls and treated groups at a significance level of 5%.

**RESULTS**

**Minimal Inhibitory Concentration (MIC)**

Psychorubrin showed a broad spectrum of antibacterial activity, with clear effectiveness against both Gram-negative and
Gram-positive bacteria. However, the three bacteria species most susceptible to psychorubrin according to MIC values were *S. aureus* 33591, *S. aureus* 33592, and *S. pyogenes* 10096, in this order (Table 1). Psychorubrin was more effective than chloramphenicol and less effective than ciprofloxacin for *S. aureus* 33591, *S. aureus* 33592, and *S. pyogenes* 10096. Based on these observations, these three bacteria strains were selected for further investigation of the psychorubrin activity.

### Bacterial Killing Assay

The psychorubrin vehicle did not affect the bacterial growth curve for all species. On the other hand, all tested bacteria showed a dose-dependent growth decrease when exposed to psychorubrin (Figure 2). All the concentrations evaluated (MIC, 0.5 MIC, and 0.25 MIC) inhibited the growth cycle curve of the three tested bacteria in comparison to the vehicle-treated control. For *S. aureus* 33591 and *S. pyogenes* 10096...
Table 1 | Antibacterial activity of the psychorubrin.

|                     | PSY  | CHL | CIP |
|---------------------|------|-----|-----|
| MIC*                |      |     |     |
| Staphylococcus aureus 25923 | 80   | 12.5| 2.5 |
| Staphylococcus aureus 33591 | 5    | 25  | 0.16|
| Staphylococcus aureus 33592 | 5    | 25  | 0.08|
| Streptococcus pyogenes 10096 | 10   | 12.5| 0.63|
| Klebsiella pneumoniae 4352 | 20   | 0.78| 0.31|
| Escherichia coli 10536 | 20   | 3.13| 0.08|
| Pseudomonas aeruginosa 9027 | 160  | 25.0| 0.63|

PSY, psychorubrin; CHL, chloramphenicol; CIP, ciprofloxacin; *Values in µg mL⁻¹.

(Figures 2A,C) psychorubrin extended the lag phase by 4 h (0.5 MIC and 0.25 MIC), and inhibited fully bacterial growth at MIC value similar to chloramphenicol. For S. aureus 33592, all concentration for psychorubrin extended the phase lag by 2 h (Figure 2B).

**Bacterial Abundance and Viability**

Fluorescence microscopy after DAPI staining showed that psychorubrin inhibited the bacterial abundance compared to the control group, reducing bacterial growth by 52, 50, and 96% for S. aureus 33591, S. aureus 33592 and S. pyogenes 10096, respectively (Figure 3A). Psychorubrin treatment produced decrease of cell density and increase of cell death.

The cytocentrifuge preparations of the cell viability probe test (Live/Dead® BacLight) revealed the presence of live (green) and dead (red) bacteria in all psychorubrin-treated and control groups (Figures 3B,C). Psychorubrin treatment induced both decrease of cell density and increase of cell death compared to control groups treated with psychorubrin vehicle.

**Nucleotide Leakage**

The efflux of nucleotides from the intracellular compartment was significant for the three Gram-positive bacteria. As shown in (Figures 4A–D) psychorubrin increased at 19, 41, and 30% the nucleotide release in S. aureus 33591, S. aureus 33592, and S. pyogenes 10096 respectively, compared to the controls.

**Checkerboard**

The checkerboard assay showed a decrease in the MIC values for both psychorubrin and chloramphenicol, suggesting possible interactions between these substances. The results demonstrated a synergistic action between psychorubrin and chloramphenicol for S. aureus 33592 and S. pyogenes 10096, and an additive effect between psychorubrin and chloramphenicol for S. aureus 33591 (Table 2).

**Effect on Established Biofilms and on Their Adhesion**

To investigate if psychorubrin was able to disrupt pre-formed biofilms and to affect their adhesion capability, samples were evaluated at the MIC and 0.5MIC (Figure 5). The disruption and adhesion of biofilm at MIC and 0.5MIC were significantly effective when compared to positive controls. In these concentrations, the inhibition of pre-formed biofilms of psychorubrin was about 56 and 46% for S. aureus 33591, 84 and 85% for S. aureus 33592, 57 and 35% for S. pyogenes 10096, respectively. Psychorubrin also decreased the adhesion of biofilms with percentages of inhibition of 49 and 12% for...
Lemos et al. Antibacterial and Antibiofilm Effects of Psychorubrin

FIGURE 4 | Mode of action of psychorubrin (PSY). Effect of psychorubrin on the amount of the total nucleotide released from S. aureus 33591 (A), S. aureus 33592 (B), and S. pyogenes 10096 (C). Area under the curve in PSY-treated and controls are showed in (D). Letters indicate statistical difference from controls treated with psychorubrin vehicle for S. aureus 33591 (a), S. aureus 33592 (b), S. pyogenes 10096 (c) (ANOVA followed by Bonferroni, P < 0.05). All experiments were carried out in triplicate, and data represent the mean ± SD.

S. aureus 33591, 52 and 42% for S. aureus 33592, 67 and 26% S. pyogenes 10096, respectively with MIC and 0.5MIC values.

Effect on Biofilm Matrix Composition
Table 3 shows the total content of carbohydrates and proteins of formed biofilms by S. aureus 33591, S. aureus 33592 and S. pyogenes 10096. Psychorubrin and chloramphenicol (MIC values) significantly reduced carbohydrate and protein contents, being the maximum reduction observed for total content of proteins.

SEM Observations
Ultrastructural analyses by SEM revealed the surface structure and morphology of biofilms formed by different bacterial strains with or without antimicrobial treatment (Figure 6). The control group showed the typical multilayer growth of bacterial biofilms (Figures 6A,D,G) while the group treated with chloramphenicol exhibited a significant reduction of biofilms only for the S. aureus 33592 and S. pyogenes 10096 strains (Figures 6B,E,H). Remarkably, psychorubrin led to a significant reduction of biofilm formation in all strains (Figures 6C,F,I), with loss of the

TABLE 2 | Fractional inhibitory concentration (FIC) indices.

| Microorganisms          | PSY | CHL | ΣFIC | Effect   |
|-------------------------|-----|-----|------|----------|
| Staphylococcus aureus 33591 | 0.078 | 12.5 | 0.52 | Additive |
| Staphylococcus aureus 33592 | 0.078 | 3.13 | 0.14 | Synergy  |
| Streptococcus pyogenes 10096 | 0.312 | 1.95  | 0.14 | Synergy  |

PSY, psychorubrin; CHL, chloramphenicol; *MIC in a combination of psychorubrin and chloramphenicol (µg/mL). ΣFIC: sum of fractional inhibitory concentrations – the combinatory effect is evaluated as follows: synergy ΣFIC ≤ 0.5; additive ΣFIC > 0.5 and ≤ 1; indifferent ΣFIC > 1 and ≤ 2.
TABLE 3 | Biochemical composition of biofilms treated with psychorubrin and chloramphenicol.

| Microorganisms          | GBC   | PSY   | CHL   |
|-------------------------|-------|-------|-------|
|                         | TP    | TC    | TP    | TC    | TP   | TC     |
| *Staphylococcus aureus* | 145.1 ± 0.2 | 0.628 ± 0.02 | 1.2 ± 0.01 | 0.148 ± 0.01 | 5.3 ± 0.07 | 0.077 ± 0.001 |
| *Staphylococcus aureus* | 153.7 ± 0.7 | 0.654 ± 0.01 | 6.7 ± 0.02 | 0.148 ± 0.03 | 7.0 ± 0.1 | 0.106 ± 0.005 |
| *Streptococcus pyogenes*| 67.2 ± 0.5 | 0.624 ± 0.03 | 0.2 ± 0.01 | 0.135 ± 0.04 | 1.0 ± 0.001 | 0.104 ± 0.06 |

GBC, growth biofilm control; PSY, psychorubrin; CHL, chloramphenicol; TP, total protein in µg mL⁻¹; TC, total carbohydrate in µg mL⁻¹.

FIGURE 6 | Biofilm scanning electron micrographs of the different bacterial strains with or without antimicrobial treatment. GC, growth control (A,D,G); CHL, chloramphenicol (B,E,H); PSY, psychorubrin (C,F,I). Note in high magnification (inset), the morphological external structure of the different bacterial strains.

bacterial original shape as evidenced by a distorted and irregular bacterial cell wall (Figure 6I). Altogether, our findings provide evidence that psychorubrin has a potent antimicrobial action against the different strains analyzed.

DISCUSSION

New antimicrobial compounds are greatly needed to treat infections caused by bacteria resistant to currently available agents. Here, we provided direct evidence that the bioactive compound psychorubrin has a broad spectrum of antibacterial activity being effective against both bacterial forms and biofilms of Gram-positive bacteria. We demonstrated a strong inhibitory activity of this agent for *S. pyogenes* and *S. aureus* including multiresistant strains. Therefore, the present study expands previous findings (Fabri et al., 2012) highlighting the use of psychorubrin as a possible strategy to treat the infections caused by these microorganisms.

The time-kill curves can monitor bacterial growth and death over a wide range of antimicrobial concentrations and have been frequently used to evaluate the effect of antimicrobials over time (Foerster et al., 2016). A time-dependent bactericidal effect happens when the concentration of the antibacterial drug surpasses the MIC for the microorganism, while the concentration-dependent bactericidal effect takes place when an antibiotic has a high concentration at the binding site to eradicate the microorganism (Anantharaman et al., 2010). Our time-kill kinetics analyses showed that psychorubrin presented a rapid time-dependent kinetics of bacterial killing for all tested bacteria, mainly at MIC value. Comparing the activity of the psychorubrin with chloramphenicol at MIC concentration, we observed a similar action starting at initial hours (Figure 2).

Psychorubrin prolonged the lag phase for the three tested bacteria (*S. aureus* 33591, *S. aureus* 33592, and *S. pyogenes* 10096) with 0.5 MIC and 0.25 MIC values. Since the lag phase is a response during the adaptation period by first division of the bacterial cell, this process could involve the repair of macromolecular damage that occurred in the ambient that the cell came from and the synthesis of cellular components necessary for growth (Baty and Delignette-Muller, 2004; Rolfe et al., 2012). Therefore, one of the possible psychorubrin targets might be the synthesis of macromolecules, since pyranonaphthoquinones and naphthoquinones can act in the redox cycle generating a pro-oxidant state that favors the occurrence of oxidative lesions in macromolecules and cellular structures thus resulting in cell death (Silva et al., 2003). In fact, we found a efficient inhibition of bacterial growth by psychorubrin during 24 h indicating a bactericidal effect of this compound, especially for *S. pyogenes* 10096. Moreover, the efficiency of psychorubrin was a little better than chloramphenicol.

To investigate the effect of psychorubrin on bacterial density and viability, we performed two additional approaches. By using fluorescent probes for DNA (DAPI staining) and membrane integrity (Backlight) (Gamalier et al., 2017), we showed that the psychorubrin treatment was able to reduce cell density and increase cell death, thus corroborating our bacterial killing assay results. The psychorubrin-elicited bacterial death may be related with a potential inhibitory effect of this compound on bacterial growth and/or a direct effect on bacterial cells, leading to cell death. Because the marker for cell viability enables the detection of compromised plasma membranes, dead
cells can be directly identified before complete cell lysis (Gamalier et al., 2017). Indeed, when cells exhibiting damaged membranes are not able to keep an electrochemical potential, they are considered dead (Joux and Lebaron, 2000). Thus, our approach was helpful to recognize bacterial viability at a single-cell level (Joux and Lebaron, 2000; Silva et al., 2014; Gamalier et al., 2017).

The significant increase of dead cells induced by psychorubrin is in accordance with previous studies, which demonstrated bactericidal activity after treatment with compounds through viability analyses using Baclight (You et al., 2013; Yuan and Yuk, 2018). Additionally, the bacteriostatic effect from chloramphenicol (Bernatová et al., 2013), showed a very low proportion of dead cells, statistically different from psychorubrin. Overall, our viability results support the potential bactericidal effect of psychorubrin for the three bacteria tested, indicating the occurrence of membrane damage. Therefore, the microscopic approaches used in the present study were especially revealing in demonstrating the mode of action of psychorubrin.

Our results showed that psychorubrin is effective against Gram-positive bacteria, but the antimicrobial activity is organism-dependent. In this context, nucleotide leakage assay was used to clarify how psychorubrin is able to inhibit proliferation of these bacteria (Hao et al., 2009). As DNA and RNA are released after membrane disruption, these nucleotides were quantified by monitoring the absorbance at 260 nm. The results of nucleotide leakage assay confirm the occurrence of membrane destabilization triggered by psychorubrin (Figure 4).

Considering antimicrobial therapy, drug combination has many advantages compared with the use of individual agents. It can be used to prevent the emergence of resistant organisms, to minimize toxicity due to the need of lower drug concentrations, and to obtain synergistic antimicrobial activity (Ocampo et al., 2014). The association of psychorubrin and chloramphenicol was important to optimize the antimicrobial effect of both. However, future studies are needed to test antimicrobial resistance to other clinical choice drugs.

One interesting observation from the present study was the efficiency of psychorubrin in disrupting pre-formed biofilms and decreasing biofilm adhesion for different bacterial species (Figure 5). These results combined with our findings showing the psychorubrin effect on biofilm matrix composition, indicate that this compound leads to the inhibition of exopolysaccharide synthesis and especially to the interference of protein formation. Altogether, our data demonstrated that psychorubrin limited the formation of biofilm. Considering that the matrix exopolysaccharide is one of the most distinctive features of a microbial biofilm, forming a three dimensional, gel-like, highly hydrated and locally charged environment in which the microorganisms are largely immobilized (Namasivayam and Roy, 2013), biofilm reduction must be considered the first step for its control by an antimicrobial agent. Furthermore, the restriction of the biochemical composition of the biofilm matrix leads to weakening of the biofilm thus facilitating the entry of the drugs (Joseph, 2003). Our SEM analyses reinforced the action of psychorubrin over the strains tested, both in biofilm form reducing the multilayer growth, and free living cells by affecting the integrity of cell wall.

CONCLUSION

Taken together, our findings identify, for the first time that psychorubrin is active against all tested Gram-positive and Gram-negative bacteria, especially S. pyogenes and S. aureus, including multi-resistant strains. Considering these two species, this compound has a bactericidal effect, targeting the bacterial synthesis of macromolecules and rapidly (2 h) destabilizing their membranes. The efficacy of psychorubrin showed to be better than chloramphenicol for S. pyogenes 10096 and the association of these agents showed at least an additive effect. The bioactivities of psychorubrin identified in this study include both planktonic and biofilm growing Gram-positive bacteria. Psychorubrin was able to reduce bacteria biofilms by interfering with protein formation and inhibiting exopolysaccharide synthesis. These results are promising. Given the potential of psychorubrin as an antibiotic drug against S. aureus and S. pyogenes, and the possible combination with chloramphenicol, this compound could be used to reduce the development of resistance to these microorganisms and improve the outcome of the therapies for infections caused by these pathogens. This is of great relevance in hospital services, especially considering the multi-resistance of MRSA.

AUTHOR CONTRIBUTIONS

AL, LC, AA, and RF designed the study. AL, LC, TS, LO, MG, and VR performed the field work and laboratory work. RM, JA, AA, and RF analyzed the data. RM, VR, ES, and RF wrote the manuscript. All authors reviewed the manuscript.

FUNDING

This work was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil) and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (Grant Number: APQ-01059-14 for RF and CBB-APQ-03647-16 for RM). Scholarships were provided by Federal University of Juiz de Fora (UFJF/Brazil and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brazil).

ACKNOWLEDGMENTS

We gratefully thank Plataforma de Microscopia Eletrônica Rudolf Barth/FIOCRUZ and Dr. Vinicius Antônio de Oliveira Dittrich (Department of Botany/UFJF) for the botanical identification of the species.
REFERENCES

Anantharaman, A., Rizvi, M. S., and Sahal, D. (2010). Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. *Antim. Agents Chem. Ther.* 54, 1693–1699. doi: 10.1128/AAC.01231-09

Babii, C., Bahrin, L. G., Neagu, A. N., Gostin, I., Mihasan, M., Birsa, L. M., et al. (2016). Antibacterial activity and proposed action mechanism of a new class of synthetic tricyclic flavonoids. *J. Appl. Microbiol.* 120, 630–663. doi: 10.1111/jam.13048

Baty, F., and Delignette-Muller, M. L. (2004). Estimating the bacterial lag time: which model, which precision? *Int. J. Food Microbiol.* 91, 261–277. doi: 10.1016/j.ijfoodmicro.2003.07.002

Bernatová, S., Samek, O., Pilát, Z., Šery, M., Ježek, J., and Jalík, P. (2013). Following the mechanisms of bacteriostatic versus bactericidal action using Raman spectroscopy. *Molecules* 18, 13188–13199. doi: 10.3390/molecules18113188

Boulos, L., Prevost, M., Barbeau, B., Coallier, J., and Desjardins, R. (1999). LIVE/DEAD® BacLight™: application of a new rapid staining method for direct enumeration of viable and total bacteria in drinking water. *J. Microbiol. Meth.* 37, 77–86. doi: 10.1016/S0167-7012(99)00048-2

Božić, D. D., Milenković, M., Ivković, B., and Ćirković, I. (2014). Antibacterial activity of three newly-synthesized chalcones & synergism with antibiotics against clinical isolates of *Staphylococcus aureus*. *Indian J. Med. Res.* 140, 130–137.

Carapetis, J. R., Steer, A. C., Mulholland, E. K., and Weber, M. (2005). The global burden of group a streptococcal diseases. *Lancet Infect. Dis.* 5, 685–694. doi: 10.1016/S1473-3099(05)70267-X

Choo, E. J. (2017). Community-associated methicillin-resistant *Staphylococcus aureus* in nosocomial infections. *Infect. Chemother.* 49, 158–159. doi: 10.3947/ic.2017.49.2.158

CLSI (2014). *Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement*. Wayne, PA: Clinical and Laboratory Standards Institute.

Dubois, M., Gilles, K. A., Hamilton, J. K., Rebers, P. A., and Smith, F. (1956). Colorimetric method for determination of sugars and related substances. *Anal. Chem.* 28, 350–356. doi: 10.1021/ac60111a017

Endale, M., Aalo, J. P., Akala, H. M., Ronn, N. K., Eyase, F. L., and Dereze, S. (2012). Antiplasmodial quinones from *Pentas longiflora* and *Pentas lanceolata*. *Planta Med.* 78, 31–35. doi: 10.1055/s-0031-1280179

Fabri, R. L., Grazul, R. M., Carvalho, L. O., Coimbra, E. S., Cardoso, G. M. M., and Souza-Fagundes, E. S. (2012). *Rubiaceae juss.* Antitumor, antibiotic and antimicrobial peptides. *Molecules* 18, 519–523. doi: 10.3390/molecules18115473

Fabri, R. L., Nogueira, M. S., Braga, F. G., Coimbra, E. S., Cardoso, L. O., and Zagan, K., Chen, Q., Liu, Q., et al. (2017). Photodynamic antimicrobial chemotherapy for *Staphylococcus aureus* and multidrug-resistant bacterial burn infection in vitro and in vivo. *Int. J. Nanomed.* 12, 5915–5931. doi: 10.2147/IJIN.S138185

Mishra, B., and Wang, G. (2017). Individual and combined effects of engineered peptides and antibiotics on *Pseudomonas aeruginosa* biofilms. *Pharmaceuticals* 10, E58. doi: 10.3390/ph10030058

Samasvayam, S. K. R., and Roy, E. A. (2013). Anti biofilm effect of medicinal plant extracts against clinical isolate of biofilm of *Escherichia coli*. *Int. J. Pharm. Pharm. Sci.* 5, 486–489.

National Nosocomial Infections Surveillance System [NNIS] (2004). National nosocomial infections surveilance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. *Am. J. Infect. Control* 32, 470–485. doi: 10.1016/j.ajic.2004.10.001

Nostro, A., Sudano Roccaro, A., Bismagni, G., Marino, A., Cannatelli, M. A., and Pizzimann, F. C. (2007). Effects of oregano, carvacrol and thymol on *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. *J. Med. Microbiol.* 56, 519–523. doi: 10.1099/jmm.0.46804-0

Ocampo, P. S., Lázár, V., Papp, B., Arnoldini, M., Wiesch, P. A., and Busa-fekete, R. (2014). Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. *Antim. Agents Chem.* 58, 4573–4582. doi: 10.1128/ACAC.02463-14

Oestergaard, L. B., Schmiegelow, M. D., Bruun, N. E., Skov, R. L., Petersen, A., and Andersen, P. S. (2017). The associations between socioeconomic status and risk of *Staphylococcus aureus* bacteremia and subsequent endocarditis—a Danish nationwide cohort study. *BMJ Infect. Dis.* 17:589. doi: 10.1186/s12879-017-2691-3

Pereira, Z. V., Carvalho-Okano, R. M., and Garcia, F. C. P. (2006). Rubiaceae juss. da reserva florestal mata do paraíso, viçosa, MG, Brasil. *Acta Bot. Brasilica* 20, 17:589. doi: 10.1590/S0102-33062006000100020

Pillai, S. K., Moellering, R. C., and Eliopoulos, G. M. (2005). “Antimicrobial activity of three newly-synthesized chalcones & synergism with antibiotics from *Mitracarpus fridgus*. *An. Acad. Bras. Ciênc.* 87, 841–852. doi: 10.1590/S0001-3762200500056

Plyuta, V., Zaitseva, J., Lobakova, E., Zagoskina, N., Kuznetsov, A., and Khmel, I. (2013). Effect of plant phenolic compounds on biofilm formation by *Pseudomonas aeruginosa* by *Staphylococcus aureus*. *APMIS* 121, 1073–1081. doi: 10.1111/apm.12083

Ribeiro, S. M., Felício, M. R., Boas, E. V., Gonçalves, S., Costa, F. F., and Samy, R. P. (2016). New frontiers for anti-biofilm drug development. *Pharmacol. Ther.* 160, 133–144. doi: 10.1016/j.pharmthera.2016.02.006

Rolfe, M. D., Rice, C. J., Lucchini, S., Pin, C., Thompson, A., and Cameron, A. D. S. (2012). Lag phase is a distinct growth phase that prepares bacteria for exponential growth and involves transient metal accumulation. *J. Bacteriol.* 194, 686–701. doi: 10.1128/JB.00612-11
Silva, M. N., Ferreira, V. F., and Souza, M. C. B. V. (2003). Um panorama atual da química e da farmacologia de naftoquinonas, com ênfase na β-lapachona e derivados. *Quim. Nova* 26, 407–416. doi: 10.1590/S0100-40422003000300019

Silva, T. P., Noyma, N. P., Duque, T. L. A., Gamalier, J. P., Vidal, L. O., Lobão, L. M., et al. (2014). Visualizing aquatic bacteria by light and transmission electron microscopy. *Antonie Van Leeuwenhoek* 105, 1–14. doi: 10.1007/s10482-013-0047-6

Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., and Provenzano, M. D. (1985). Measurement of protein using bicinchoninic acid. *Anal. Biochem.* 150, 176–185. doi: 10.1016/0003-2697(85)90444-2

Stefani, S., Chung, D. R., Lindsay, J. A., Friedrich, A. W., Kearns, A. M., Westh, H., et al. (2012). Meticillin-resistant *Staphylococcus aureus* (MRSA): global epidemiology and harmonisation of typing methods. *Int. J. Antimic. Agents* 39, 273–282. doi: 10.1016/j.ijantimicag.2011.09.030

Subramani, R., Narayanasamy, M., and Feussner, K. D. (2017). Plant-derived antimicrobials to fight against multi-drug-resistant human pathogens. *3 Biotech* 7:172. doi: 10.1007/s13205-017-0848-9

Tang, Y. L., Shi, Y. H., Zhao, W., Hao, G., and Le, G. W. (2008). Insertion mode of a novel anionic antimicrobial peptide MDpep5 (Val-Glu-Ser-Trp-Val) from Chinese traditional edible larvae of housefly and its effect on surface potential of bacterial membrane. *J. Pharm Biom. Anal.* 48, 1187–1194. doi: 10.1016/j.jpba.2008.09.006

Wilson, S. E., Graham, D. R., Wang, W., Bruss, J. B., and Castaneda-Ruiz, B. (2017). Telavancin in the treatment of concurrent *Staphylococcus aureus* bacteremia: a retrospective analysis of ATLAS and ATTAIN studies. *Infect. Dis. Ther.* 6, 413–422. doi: 10.1007/s40121-017-0162-1

Wu, H., Moser, C., Wang, H. Z., Hoiby, N., and Song, Z. J. (2015). Strategies for combating bacterial biofilm infections. *Int. J. Oral Sci.* 7, 1–7. doi: 10.1038/ijos.2014.65

You, Y. O., Choi, N. Y., Kang, S. Y., and Kim, K. J. (2013). Antibacterial activity of *Rhus javanica* against methicillin-resistant *Staphylococcus aureus*. *Evid. Based Complement. Alternat. Med.* 2013, 1–8. doi: 10.1155/2013/549207

Yuan, W., and Yuk, H. G. (2018). Antimicrobial efficacy of *Syzygium antisepticum* plant extract against *Staphylococcus aureus* and methicillin-resistant *S. aureus* and its application potential with cooked chicken. *Food Microbiol.* 72, 176–184. doi: 10.1016/j.fm.2017.12.002

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Lemos, Campos, Melo, Oliveira, Silva, Melo, Rocha, Aguiar, Apolônio, Scio and Fabri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.